mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways (original) (raw)
Maehama, T. & Dixon, J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem.273, 13375–13378 (1998). ArticleCAS Google Scholar
del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. & Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science278, 687–689 (1997). ArticleCAS Google Scholar
Kops, G.J. et al. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature398, 630–634 (1999). ArticleCAS Google Scholar
Nakamura, N. et al. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol.20, 8969–8982 (2000). ArticleCAS Google Scholar
Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M. & Hemmings, B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature378, 785–789 (1995). ArticleCAS Google Scholar
Goberdhan, D.C., Paricio, N., Goodman, E.C., Mlodzik, M. & Wilson, C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev.13, 3244–3258 (1999). ArticleCAS Google Scholar
Oldham, S., Montagne, J., Radimerski, T., Thomas, G. & Hafen, E. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev.14, 2689–2694 (2000). ArticleCAS Google Scholar
Neshat, M.S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA98, 10314–10319 (2001). ArticleCAS Google Scholar
Podsypanina, K. et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc. Natl. Acad. Sci. USA98, 10320–10325 (2001). ArticleCAS Google Scholar
Aoki, M., Blazek, E. & Vogt, P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA98, 136–141 (2001). ArticleCAS Google Scholar
Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J. & Cantley, L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell10, 151–162 (2002). ArticleCAS Google Scholar
Gao, X. et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol.4, 699–704 (2002). ArticleCAS Google Scholar
Gao, X. & Pan, D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev.15, 1383–192 (2001). ArticleCAS Google Scholar
Potter, C.J., Huang, H. & Xu, T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell105, 357–368 (2001). ArticleCAS Google Scholar
Tee, A.R., Manning, B.D., Roux, P.P., Cantley, L.C. & Blenis, J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol.13, 1259–1268 (2003). ArticleCAS Google Scholar
Huang, S. & Houghton, P.J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Invest. Drugs3, 295–304 (2002). CAS Google Scholar
Majumder, P.K. et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc. Natl. Acad. Sci. USA100, 7841–7846 (2003). ArticleCAS Google Scholar
Nashan, B. Early clinical experience with a novel rapamycin derivative. Ther. Drug Monit.24, 53–58 (2002). ArticleCAS Google Scholar
Raught, B. et al. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J.19, 434–444 (2000). ArticleCAS Google Scholar
Bruckheimer, E.M. et al. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo. Oncogene19, 2404–2412 (2000). ArticleCAS Google Scholar
Mootha, V.K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet.34, 267–273 (2003). ArticleCAS Google Scholar
Semenza, G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol.64, 993–998 (2002). ArticleCAS Google Scholar
Sellers, W.R. & Sawyers, C.A. Somatic genetics of prostate cancer: oncogenes and Tumor Suppressors. in Prostate Cancer Principles and Practice (ed. Kantoff, P.) (Lippincott Williams & Wilkins, Philadelphia, USA, 2002). Google Scholar
Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science304, 554 (2004). ArticleCAS Google Scholar
Shayesteh, L. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet.21, 99–102 (1999). ArticleCAS Google Scholar
Debnath, J. et al. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell111, 29–40 (2002). ArticleCAS Google Scholar
Debnath, J., Walker, S.J. & Brugge, J.S. Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J. Cell. Biol.163, 315–326 (2003). ArticleCAS Google Scholar
Wendel, H.G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature428, 332–337 (2004). ArticleCAS Google Scholar
Edinger, A.L. & Thompson, C.B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell13, 2276–2288 (2002). ArticleCAS Google Scholar
McDonnell, T.J. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res.52, 6940–6944 (1992). CASPubMed Google Scholar
Furuya, Y., Krajewski, S., Epstein, J.I., Reed, J.C. & Isaacs, J.T. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin. Cancer Res.2, 389–398 (1996). CASPubMed Google Scholar
Krajewska, M. et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol.148, 1567–1576 (1996). CASPubMedPubMed Central Google Scholar
Colombel, M. et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am. J. Pathol.143, 390–400 (1993). CASPubMedPubMed Central Google Scholar
Baltaci, S., Orhan, D., Ozer, G., Tolunay, O. & Gogous, O. Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia. BJU Int.85, 155–159 (2000). ArticleCAS Google Scholar
McMenamin, M.E. et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res.59, 4291–4296 (1999). CASPubMed Google Scholar
Suzuki, H. et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res.58, 204–209 (1998). CAS Google Scholar
Huang, H. et al. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem.276, 38830–38836 (2001). ArticleCAS Google Scholar
Mita, M.M., Mita, A. & Rowinsky, E.K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer4, 126–137 (2003). ArticleCAS Google Scholar
Hidalgo, M. & Rowinsky, E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene19, 6680–6686 (2000). ArticleCAS Google Scholar
Chi, K.N. et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res.7, 3920–3927 (2001). CASPubMed Google Scholar
Morris, M.J. et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res.8, 679–683 (2002). CASPubMed Google Scholar
DiPaola, R.S. et al. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J. Clin. Oncol.17, 2213–2218 (1999). ArticleCAS Google Scholar
Friedland, D. et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin. Oncol.26, 19–23 (1999). CASPubMed Google Scholar
Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer3, 721–732 (2003). ArticleCAS Google Scholar
Abraham, R.T. mTOR as a positive regulator of tumor cell responses to hypoxia. Curr. Top. Microbiol. Immunol.279, 299–319 (2004). CASPubMed Google Scholar
Hudson, C.C. et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol.22, 7004–7014 (2002). ArticleCAS Google Scholar
Zhong, H. et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res.60, 1541–1545 (2000). CASPubMed Google Scholar
Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G.L. & Van Obberghen, E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem.277, 27975–27981 (2002). ArticleCAS Google Scholar
Brugarolas, J.B., Vazquez, F., Reddy, A., Sellers, W.R. & Kaelin, W.G., Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell4, 147–158 (2003). ArticleCAS Google Scholar
Taesch, S. & Niese, D. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients. Transpl. Int.7 (suppl. 1), S263–S266 (1994). Article Google Scholar